Based on these results, we propose FGFR1 inhibitors in combination with ER and CDK4/6 antagonists as a testable therapeutic strategy in ER+ breast cancers also harboring aberrant FGFR signaling as a result of FGFR pathway gene alterations. Here, ESR1 is linked to breast cancer.